RxDoctor Payments Data

Lacy Harrington

Family · Neosho, MONPI 1376268755

Payments from drug & device makers

$5,738in general payments, 2019–2025

Across 387 payments — averaging $14.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$976
  • AbbVie$763
  • Novo Nordisk$644
  • Amgen$469
  • GSK$314
  • Otsuka America Pharmaceutical, Inc.$281
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$5,738100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,738 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$131,806
MounjaroTirzepatide49$50,733
VraylarCariprazine Hcl30$44,045
FarxigaDapagliflozin Propanediol58$43,971
XareltoRivaroxaban30$30,197
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog38$26,796
JardianceEmpagliflozin30$24,136
EliquisApixaban19$24,018
Spiriva RespimatTiotropium Bromide34$22,103
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog50$21,975
MyrbetriqMirabegron32$17,372
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$15,377
Breo ElliptaFluticasone/Vilanterol33$13,419
Repatha SureclickEvolocumab15$12,693
Praluent PenAlirocumab17$12,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$644$131,806106 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$976$65,70393 claims
AbbVieVraylar, Linzess$763$55,41644 claims
Lilly USA, LLCMounjaro$267$50,73349 claims
Boehringer IngelheimJardiance, Spiriva Respimat$139$46,23964 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Arexvy$314$37,23385 claims
Johnson & JohnsonXarelto$103$30,19730 claims
PfizerEliquis$225$24,01819 claims
Astellas Pharma US IncMyrbetriq$47$17,37232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.

Other family in Neosho

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →